These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11331332)

  • 41. Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
    Flaherty KT; Stevenson JP; Hahn SM; Redlinger M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):217-22. PubMed ID: 12811513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
    Nogué-Aliguer M; Carles J; Arrivi A; Juan O; Alonso L; Font A; Mellado B; Garrido P; Sáenz A;
    Cancer; 2003 May; 97(9):2180-6. PubMed ID: 12712469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
    Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
    Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
    Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
    J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
    Xu N; Zhang XC; Xiong JP; Fang WJ; Yu LF; Qian J; Zhang L
    BMC Cancer; 2007 Jun; 7():98. PubMed ID: 17559681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
    Bellmunt J; de Wit R; Albanell J; Baselga J
    Eur J Cancer; 2001 Nov; 37(17):2212-5. PubMed ID: 11677109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
    DiPaola RS; Rubin E; Toppmeyer D; Eid J; Butzbach D; Dvorzhinski D; Capanna T; Cairdella M; Shih JW; Goodin S; Todd MB
    Med Sci Monit; 2003 Feb; 9(2):PI5-11. PubMed ID: 12601301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.
    Redman BG; Smith DC; Flaherty L; Du W; Hussain M
    J Clin Oncol; 1998 May; 16(5):1844-8. PubMed ID: 9586899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
    Balar AV; Apolo AB; Ostrovnaya I; Mironov S; Iasonos A; Trout A; Regazzi AM; Garcia-Grossman IR; Gallagher DJ; Milowsky MI; Bajorin DF
    J Clin Oncol; 2013 Feb; 31(6):724-30. PubMed ID: 23341513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
    Matsumoto K; Irie A; Satoh T; Okazaki M; Iwamura M; Baba S
    Int J Urol; 2007 Nov; 14(11):1000-4; discussion 1004. PubMed ID: 17956525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
    Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
    Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
    Greco FA; Burris HA; Litchy S; Barton JH; Bradof JE; Richards P; Scullin DC; Erland JB; Morrissey LH; Hainsworth JD
    J Clin Oncol; 2002 Mar; 20(6):1651-6. PubMed ID: 11896116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
    Sadeghi S; Groshen SG; Tsao-Wei DD; Parikh R; Mortazavi A; Dorff TB; Kefauver C; Hoimes C; Doyle L; Quinn DI; Newman E; Lara PN
    J Clin Oncol; 2019 Oct; 37(29):2682-2688. PubMed ID: 31390274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
    Smith DC; Mackler NJ; Dunn RL; Hussain M; Wood D; Lee CT; Sanda M; Vaishampayan U; Petrylak DP; Quinn DI; Beekman K; Montie JE
    J Urol; 2008 Dec; 180(6):2384-8; discussion 2388. PubMed ID: 18930256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
    Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
    Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
    Lara PN; Meyers FJ; Law LY; Dawson NA; Houston J; Lauder I; Edelman MJ
    Cancer; 2004 Jan; 100(1):82-8. PubMed ID: 14692027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
    Song Y; Yang L; Zhou A; Chi Y; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.